Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Paolo Strati, Wei-Gang Tong, Candida Vitale, William G. Wierda, Susan O’Brien, Jennifer R. Brown, Wen-Kai Weng, Thomas Kipps, Michael J. Keating & Alessandra Ferrajoli. (2015) A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 56:6, pages 1878-1880.
Read now
Read now
Guillaume Cartron. (2009) FCGR3A polymorphism story: a new piece of the puzzle. Leukemia & Lymphoma 50:9, pages 1401-1402.
Read now
Read now
Articles from other publishers (22)
Taozhu Fu, Lianfeng Zhang, Meini Zuo, Feng Li, Changjin Shi & Hongrun Chen. (2023) FCGR2A as one novel potential target for poor survival prognosis of clear cell renal cell carcinoma. Medicine 102:11, pages e33324.
Crossref
Crossref
Jonathan C. Strefford, Malgorzata NowickaChantal E. HargreavesCathy BurtonAndrew DaviesRosalind GandertonWolfgang HiddemannChisako IriyamaWolfram Klapper, Kate V. LathamMaurizio MartelliFarheen MirHelen ParkerKathleen N. PotterMatthew J. J. Rose-Zerilli, Laurie H. SehnMarek Trněný, Umberto Vitolo, Christopher R. BolenChristian Klein, Andrea KnappMikkel Z. OestergaardMark S. Cragg. (2021) Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Advances 5:15, pages 2935-2944.
Crossref
Crossref
Marie Denis Musquer, Nicolas Jouand, Morgane Pere, Juliette Eugène Lamer, Stéphane Bézieau, Tamara Matysiak, Roger Faroux, François-Xavier Caroli Bosc, Marie-Christine Rousselet, François Leclair, Jean-François Mosnier, Claire Toquet, Nadine Gervois & Céline Bossard. (2021) High-Density of FcγRIIIA+ (CD16+) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis. Frontiers in Oncology 11.
Crossref
Crossref
Cecilia Nakid-Cordero, Marine Baron, Amélie Guihot & Vincent Vieillard. (2021) Natural Killer Cells in Post-Transplant Lymphoproliferative Disorders. Cancers 13:8, pages 1836.
Crossref
Crossref
Noa Granot, Andrew R. Rezvani, Barbara S. Pender, Barry E. Storer, Brenda M. Sandmaier, Rainer Storb & David G. Maloney. (2020) Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. Biology of Blood and Marrow Transplantation 26:10, pages 1811-1818.
Crossref
Crossref
Veena A. Thomas & Joseph P. Balthasar. (2019) Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. Antibodies 8:4, pages 56.
Crossref
Crossref
Pallawi Torka, Mathew Barth, Robert Ferdman & Francisco J. Hernandez-Ilizaliturri. (2019) Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. Current Hematologic Malignancy Reports 14:5, pages 426-438.
Crossref
Crossref
Matthew J. Barth & Stanton C. Goldman. 2019. Resistance to Targeted Therapies in Lymphomas. Resistance to Targeted Therapies in Lymphomas
27
55
.
Xinjian Chen. (2018) Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy. EMJ Hematology, pages 82-90.
Crossref
Crossref
Amy K. Erbe, Wei Wang, Patrick K. Reville, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Wendy B. London, Arlene Naranjo, Fangxin Hong, Michael D. Hogarty, John M. Maris, Julie R. Park, M. F. Ozkaynak, Jeffrey S. Miller, Andrew L. Gilman, Brad Kahl, Alice L. Yu & Paul M. Sondel. (2017) HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in Immunology 8.
Crossref
Crossref
Michael Kasperkiewicz, Christoph T. Ellebrecht, Hayato Takahashi, Jun Yamagami, Detlef Zillikens, Aimee S. Payne & Masayuki Amagai. (2017) Pemphigus. Nature Reviews Disease Primers 3:1.
Crossref
Crossref
Amy K. Erbe, Wei Wang, Jacob Goldberg, Mikayla Gallenberger, KyungMann Kim, Lakeesha Carmichael, Dustin Hess, Eneida A. Mendonca, Yiqiang Song, Jacquelyn A. Hank, Su-Chun Cheng, Sabina Signoretti, Michael Atkins, Alexander Carlson, James W. Mier, David J. Panka, David F. McDermott & Paul M. Sondel. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clinical Cancer Research 23:9, pages 2159-2168.
Crossref
Crossref
Marina Moskalenko, Michael Pan, Yichun Fu, Ellen H. de Moll, Daigo Hashimoto, Arthur Mortha, Marylene Leboeuf, Padmini Jayaraman, Sebastian Bernardo, Andrew G. Sikora, Jedd Wolchok, Nina Bhardwaj, Miriam Merad & Yvonne Saenger. (2015) Requirement for Innate Immunity and CD90+ NK1.1− Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy. Cancer Immunology Research 3:3, pages 296-304.
Crossref
Crossref
Sven de Vos, Andres Forero-Torres, Stephen M Ansell, Brad Kahl, Bruce D Cheson, Nancy L Bartlett, Richard R Furman, Jane N Winter, Henry Kaplan, John Timmerman, Nancy C Whiting, Jonathan G Drachman & Ranjana Advani. (2014) A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology & Oncology 7:1.
Crossref
Crossref
Francisco J. Hernandez-Ilizaliturri & Myron S. Czuczman. 2013. Resistance to Immunotherapeutic Antibodies in Cancer. Resistance to Immunotherapeutic Antibodies in Cancer
73
92
.
C. Keane, J. P. Nourse, P. Crooks, D. Nguyen-Van, H. Mutsando, P. Mollee, R. A. Lea & M. K. Gandhi. (2012)
Homozygous
FCGR3A-158V
alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma
. Internal Medicine Journal 42:10, pages 1113-1119.
Crossref
Crossref
Hervé GhesquièresGuillaume CartronJohn Francis SeymourMarie-Hélène Delfau-LarueFritz OffnerPierre SoubeyranAurore PerrotPauline BriceRéda BouabdallahAnne SonetJehan DupuisOlivier CasasnovasJohn Vincent CatalanoAlain DelmerFabrice JardinAurélie VerneyPeggy Dartigues & Gilles Salles. (2012) Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 120:13, pages 2650-2657.
Crossref
Crossref
Hong‐Zhen Xia, Wei‐Dong Du, Qiang Wu, Gang Chen, Yuan Zhou, Xian‐Fa Tang, Hua‐Yang Tang, Yi Liu, Feng Yang, Jian Ruan, Song Xu, Xian‐Bo Zuo & Xue‐Jun Zhang. (2011) E‐selectin rs5361 and FCGR2A rs1801274 variants were associated with increased risk of gastric cancer in a Chinese population. Molecular Carcinogenesis 51:8, pages 597-607.
Crossref
Crossref
Andrew R. Rezvani & David G. Maloney. (2011) Rituximab resistance. Best Practice & Research Clinical Haematology 24:2, pages 203-216.
Crossref
Crossref
Christian Grimstein & Jane PF Bai. (2011) Individualizing therapy of monoclonal antibodies and fusion proteins: emerging potential in the age of personalized medicine. Therapeutic Delivery 2:3, pages 369-381.
Crossref
Crossref
Yun Zhuang, Wei Xu, Yunfeng Shen & Jianyong Li. (2010) Fcγ Receptor Polymorphisms and Clinical Efficacy of Rituximab in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 10:5, pages 347-352.
Crossref
Crossref
Wen-Kai WengRobert S. NegrinPhilip LavoriSandra J. Horning. (2010) Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 28:2, pages 279-284.
Crossref
Crossref